



**CURESEARCH FOR CHILDREN'S CANCER**

**FINANCIAL STATEMENTS  
AND SUPPLEMENTARY INFORMATION**

**DECEMBER 31, 2014 AND 2013**

## TABLE OF CONTENTS

	<u>Page Numbers</u>
Independent Auditor's Report.....	1
Statements of Financial Position .....	2
Statements of Activities .....	3-4
Statements of Cash Flows .....	5
Notes to Financial Statements .....	6-16
Supplementary Information:	
Independent Auditor's Report on Supplementary Information .....	17
Schedules of Functional Expenses .....	18-19

To the Board of Directors  
CureSearch for Children's Cancer

### **Independent Auditor's Report**

We have audited the accompanying financial statements of CureSearch for Children's Cancer (a non-profit organization), which comprise the statements of financial position as of December 31, 2014 and 2013, and the related statements of activities and cash flows for the years then ended, and the related notes to the financial statements.

#### **Management's Responsibility for the Financial Statements**

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

#### **Auditor's Responsibility**

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

#### **Opinion**

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of CureSearch for Children's Cancer as of December 31, 2014 and 2013 and the changes in its net assets, and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

*Gross, Mendelsohn & Associates, P.A.*

Baltimore, Maryland  
July 14, 2015

**CURESEARCH FOR CHILDREN'S CANCER**  
**Statements of Financial Position**  
**December 31, 2014 and 2013**

	<u>2014</u>	<u>2013</u>
<b>Assets</b>		
<b>Current Assets</b>		
Cash and cash equivalents	\$ 883,006	\$ 543,841
Accounts receivable	78,904	213,522
Contributions receivable	-0-	71,738
Investments, current portion	3,722,211	4,658,573
Prepaid expenses	81,603	79,217
Total Current Assets	<u>4,765,724</u>	<u>5,566,891</u>
<b>Property</b> , net of accumulated depreciation	<u>142,663</u>	<u>38,131</u>
<b>Other Assets</b>		
Investments, long-term portion	2,500,000	2,500,000
Assets held in trust	20,419	-0-
Deposits	33,459	31,459
Total Other Assets	<u>2,553,878</u>	<u>2,531,459</u>
<b>Total Assets</b>	<u><u>\$ 7,462,265</u></u>	<u><u>\$ 8,136,481</u></u>
<b>Liabilities and Net Assets</b>		
<b>Current Liabilities</b>		
Accounts payable and accrued expenses	\$ 225,013	\$ 474,264
Deferred revenue	5,040	32,053
Deferred rent, current portion	28,383	16,113
Total Current Liabilities	<u>258,436</u>	<u>522,430</u>
<b>Non-Current Liabilities</b>		
Deferred rent, non-current portion	150,784	4,470
Deferred compensation	20,419	-0-
Total Non-Current Liabilities	<u>171,203</u>	<u>4,470</u>
<b>Total Liabilities</b>	<u>429,639</u>	<u>526,900</u>
<b>Commitments</b> (Notes 7, 8 and 9)		
<b>Net Assets</b>		
Unrestricted	1,555,951	1,623,300
Temporarily restricted	2,976,675	3,486,281
Permanently restricted	2,500,000	2,500,000
Total Net Assets	<u>7,032,626</u>	<u>7,609,581</u>
<b>Total Liabilities and Net Assets</b>	<u><u>\$ 7,462,265</u></u>	<u><u>\$ 8,136,481</u></u>

The accompanying notes are an integral part of these financial statements.

**CURESEARCH FOR CHILDREN'S CANCER**  
**Statements of Activities**  
**For the Years Ended December 31, 2014 and 2013**

	<b>2014</b>			
	<b>Unrestricted</b>	<b>Temporarily Restricted</b>	<b>Permanently Restricted</b>	<b>Total</b>
<b>Support and Revenue</b>				
Contributions	\$ 1,388,250	\$ 614,523	\$ -0-	\$ 2,002,773
Grants and government contracts	-0-	-0-	-0-	-0-
Institutional grants and gifts	5,000	10,000	-0-	15,000
Cause and marketing revenue	114,056	-0-	-0-	114,056
Special events, net	3,297,240	369,006	-0-	3,666,246
Investment income	22,058	165,038	-0-	187,096
Other revenue	41,814	-0-	-0-	41,814
Net assets released from restrictions:				
Satisfaction of program restrictions	1,668,173	(1,668,173)	-0-	-0-
Satisfaction of time restrictions	-0-	-0-	-0-	-0-
Total Support and Revenue	<u>6,536,591</u>	<u>(509,606)</u>	<u>-0-</u>	<u>6,026,985</u>
<b>Expenses</b>				
Program services	<u>3,211,384</u>	<u>-0-</u>	<u>-0-</u>	<u>3,211,384</u>
Support services				
Fundraising	2,435,183	-0-	-0-	2,435,183
Management and general	957,373	-0-	-0-	957,373
Total Support Services	<u>3,392,556</u>	<u>-0-</u>	<u>-0-</u>	<u>3,392,556</u>
Total Expenses	<u>6,603,940</u>	<u>-0-</u>	<u>-0-</u>	<u>6,603,940</u>
<b>Change in Net Assets</b>	<b>(67,349)</b>	<b>(509,606)</b>	<b>-0-</b>	<b>(576,955)</b>
<b>Net Assets at Beginning of Year</b>	<u>1,623,300</u>	<u>3,486,281</u>	<u>2,500,000</u>	<u>7,609,581</u>
<b>Net Assets at End of Year</b>	<u>\$ 1,555,951</u>	<u>\$ 2,976,675</u>	<u>\$ 2,500,000</u>	<u>\$ 7,032,626</u>

**2013**

<b>Unrestricted</b>	<b>Temporarily Restricted</b>	<b>Permanently Restricted</b>	<b>Total</b>
\$ 1,391,225	\$ 559,432	\$ -0-	\$ 1,950,657
95,043	-0-	-0-	95,043
5,500	136,500	-0-	142,000
104,116	-0-	-0-	104,116
4,020,882	305,405	-0-	4,326,287
7,929	300,360	-0-	308,289
137,375	-0-	-0-	137,375
2,734,203	(2,734,203)	-0-	-0-
261,344	(261,344)	-0-	-0-
8,757,617	(1,693,850)	-0-	7,063,767
5,542,090	-0-	-0-	5,542,090
2,417,239	-0-	-0-	2,417,239
1,003,058	-0-	-0-	1,003,058
3,420,297	-0-	-0-	3,420,297
8,962,387	-0-	-0-	8,962,387
(204,770)	(1,693,850)	-0-	(1,898,620)
1,828,070	5,180,131	2,500,000	9,508,201
<u>\$ 1,623,300</u>	<u>\$ 3,486,281</u>	<u>\$ 2,500,000</u>	<u>\$ 7,609,581</u>

The accompanying notes are an integral part of these financial statements.

**CURESEARCH FOR CHILDREN'S CANCER**  
**Statements of Cash Flows**  
**For the Years Ended December 31, 2014 and 2013**

	<u>2014</u>	<u>2013</u>
<b>Cash Flows From Operating Activities</b>		
Change in net assets	\$ (576,955)	\$ (1,898,620)
Adjustments to reconcile change in net assets to net cash used in operating activities:		
Depreciation	33,467	65,652
Net losses (gains) on investments	92,658	(176,836)
Donated stock contributions	(76,541)	(46,602)
Changes in operating assets and liabilities:		
Accounts receivable	134,618	2,284,490
Contributions receivable	71,738	261,344
Prepaid expenses	(2,386)	18,287
Deposits	(2,000)	9,449
Accounts payable and accrued expenses	(249,251)	(1,715,837)
Deferred revenue	(27,013)	(283,802)
Deferred rent	158,584	(9,081)
Deferred compensation	20,419	-0-
Net Cash Used in Operating Activities	<u>(422,662)</u>	<u>(1,491,556)</u>
<b>Cash Flows From Investing Activities</b>		
Proceeds from sales of investments	2,875,699	3,264,265
Purchases of investments	(2,031,994)	(1,988,119)
Net proceeds from sale of donated stock	76,541	46,602
Increase in assets held in trust	(20,419)	-0-
Purchase of property	(138,000)	-0-
Net Cash Provided by Investing Activities	<u>761,827</u>	<u>1,322,748</u>
<b>Net Increase (Decrease) in Cash and Cash Equivalents</b>	<b>339,165</b>	<b>(168,808)</b>
<b>Cash and Cash Equivalents at Beginning of Year</b>	<u>543,841</u>	<u>712,649</u>
<b>Cash and Cash Equivalents at End of Year</b>	<u>\$ 883,006</u>	<u>\$ 543,841</u>

The accompanying notes are an integral part of these financial statements.

**CURESEARCH FOR CHILDREN'S CANCER**  
**Notes to Financial Statements**  
**December 31, 2014 and 2013**

**Note 1: Summary of Significant Accounting Policies**

CureSearch for Children's Cancer (CureSearch) was incorporated under the laws of the state of California on November 1, 1987 and has been recognized by the Internal Revenue Service (IRS) as a tax-exempt, publicly supported organization, as defined by section 501(c)(3) of the Internal Revenue Code (IRC), and, therefore is not a private foundation. CureSearch was previously known as the National Childhood Cancer Foundation.

CureSearch's mission is to fund and support targeted and innovative cancer research with measurable results, and to be the authoritative source of information and resources for all those affected by children's cancer. CureSearch supports childhood cancer research at all stages along the research continuum, from fellowships that accelerate the careers of young researchers to multi-million dollar grants that support research teams developing potential new treatments, to clinical trial awards that enable hospitals to enroll children being treated today. It provides educational resources to parents and caregivers, including plain language information on diagnosis and treatment, procedural videos, and parent webinars. CureSearch also raises funds through individuals, corporations, private foundations, and special events.

The accounting and reporting policies of CureSearch conform to accounting principles generally accepted in the United States of America. Following is a description of the most significant of those policies:

Financial Statement Presentation: CureSearch reports information regarding its financial position and activities according to three classes of net assets: unrestricted net assets, temporarily restricted net assets, and permanently restricted net assets.

Use of Estimates: The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Cash and Cash Equivalents: CureSearch classifies all investments which are readily convertible to cash and which have a maturity of three months or less when purchased as cash equivalents.

Accounts Receivable: Accounts receivable arise from services rendered and are carried at original invoice amount less an estimate made for doubtful receivables. CureSearch utilizes the reserve method of accounting for bad debts. Management establishes the allowance for doubtful accounts based on industry experience and its historical collection experience with individual accounts. Receivables are written off by management when, in their determination, all reasonable collection efforts have been exhausted. Recoveries of receivables previously written off are recorded when collected. Management has determined that all accounts receivables at December 31, 2014 and 2013 are fully collectible and therefore, has not recorded an allowance for doubtful accounts.



**CURESEARCH FOR CHILDREN'S CANCER**  
**Notes to Financial Statements**  
**December 31, 2014 and 2013**

**Note 1: Summary of Significant Accounting Policies (Continued)**

Contributions Receivable: Unconditional promises to give are recorded as contributions receivable and recognized as revenue in the period received. A provision is made for uncollectible contributions based on anticipated collection losses. Estimated losses are generally determined from historical collection experience and a review of outstanding contributions receivable. Contributions receivable are written off by management when, in its determination, all appropriate collection efforts have been taken. Management has determined that all contributions receivable at December 31, 2014 and 2013 are fully collectible and therefore, has not recorded an allowance for doubtful accounts.

Investments: Investments with readily determinable fair values are reported at fair value in the statements of financial position. Investments, whose fair values are not readily determinable, are recorded at cost. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Realized and unrealized gains and losses on investments for the year are reported in the statements of activities as part of investment income (loss), net.

CureSearch invests in a professionally managed portfolio that may contain corporate bonds, mutual funds, money market funds and other investments. Such investments are exposed to various risks such as interest rate, market, and credit. Due to the level of risk associated with such investments and the level of uncertainty related to changes in the value of such investments, it is at least reasonably possible that changes in risks in the near term could materially affect investment balances and the amounts reported in the financial statements.

Property and Depreciation: Property is recorded at cost or, if donated, at fair value at the date of contribution, less accumulated depreciation. CureSearch capitalizes all property acquisitions in excess of \$5,000 having an estimated useful life greater than one year. Expenditures for maintenance and routine repairs are charged to expense as incurred; expenditures for improvements and major repairs that materially extend the useful lives of assets are capitalized. Depreciation is computed using the straight-line method and is charged to expense over the estimated useful lives of the assets as follows:

Furniture and fixtures	8 years
Leasehold improvements	3-5 years
Computers and equipment	3-5 years

Deferred Rent: CureSearch entered into a lease agreement for office space which provided for a period of rent abatement and contains annual rent escalations. As a result, CureSearch is recognizing rent expense over a straight-line basis over the term of the lease. Deferred rent represents the difference between rent expense recognized to date and the actual payments made to date.

Revenue Recognition: CureSearch derives revenue primarily from fee for service contracts, grants, contributions, and investment income. Fee for service contracts and investment revenue are recognized as revenue when earned. Unconditional contributions are recognized in the year the contributions are pledged and/or received. Conditional grants are earned and recognized as revenue in proportion to the related expenditures incurred or when all conditions of the grant have been substantially met. Grants and contributions earned but not yet received are recorded as accounts/contributions receivable. Grant proceeds received in advance and not yet earned are recorded as deferred revenue.

**CURESEARCH FOR CHILDREN'S CANCER**  
**Notes to Financial Statements**  
**December 31, 2014 and 2013**

**Note 1: Summary of Significant Accounting Policies (Continued)**

Contributions: Contributions received are recorded as unrestricted, temporarily restricted, or permanently restricted support depending on the existence and/or nature of any donor restrictions.

Recognition of Donor Restrictions: Donor-restricted support is reported as an increase in temporarily or permanently restricted net assets, depending on the nature of the restriction. Upon the expiration of a restriction, temporarily restricted net assets are reclassified to unrestricted net assets in the statements of activities.

Functional Allocation of Expenses: The costs of providing various programs and other support activities have been summarized on a functional basis in the statements of activities. Costs that can be identified with specific programs or support services are allocated directly. Costs that cannot be specifically identified with a particular function and that benefit more than one functional category are allocated based on estimates.

Contributed Services: Donated services are recognized as contributions if the services (a) create or enhance nonfinancial assets or (b) require specialized skills, are performed by individuals with those skills, and would otherwise be purchased by CureSearch.

During the years ended December 31, 2014 and 2013, in-kind contribution revenue consisted of advertising services in the amount of \$78,857 and \$-0-, respectively. The advertising expense has been reported by its functional classification in the statements of activities.

Advertising: Advertising costs are charged to operations when incurred. CureSearch had no significant direct-response advertising. Advertising expense for the years ended December 31, 2014 and 2013 totaled \$80,243 (including the \$78,857 donated amount) and \$5,683, respectively.

Income Taxes: CureSearch is exempt from federal and state income taxes under Internal Revenue Code §501(c)(3). Income which is not related to exempt purposes, less applicable deductions, is subject to federal and state corporate income taxes. CureSearch had no unrelated business income for the years ended December 31, 2014 and 2013. Accordingly, no provision for income taxes is reflected in these financial statements.

CureSearch's federal exempt organization tax returns are subject to examination by the IRS, generally for a period of three years after the returns are filed.

Subsequent Events: In preparing these financial statements, CureSearch has evaluated events and transactions for potential recognition or disclosure through July 14 2015, the date the financial statements were available to be issued. During the period from January 1, 2015 through July 14, 2015, CureSearch did not have any material recognizable subsequent events.

**CURESEARCH FOR CHILDREN'S CANCER**  
**Notes to Financial Statements**  
**December 31, 2014 and 2013**

**Note 2: Investments**

A summary of the investment portfolio is as follows at December 31, 2014 and 2013:

	2014		2013	
	Fair Value	Cost	Fair Value	Cost
Corporate bonds, fixed income	\$ 3,840,951	\$ 3,827,192	\$ 2,521,733	\$ 2,492,385
Exchange traded funds, equity	1,418,108	756,834	1,259,191	660,540
Money market funds	450,819	450,819	2,747,630	2,747,630
Exchange traded funds, fixed income	408,379	371,130	372,745	361,216
Mutual funds, equity	54,403	54,951	136,185	114,438
Mutual funds, international equity	49,551	50,103	121,089	120,559
Total investments	6,222,211	<u>\$ 5,511,029</u>	7,158,573	<u>\$ 6,496,768</u>
Investments classified as long-term:				
Endowment funds	<u>2,500,000</u>		<u>2,500,000</u>	
Investments, current portion	<u>\$ 3,722,211</u>		<u>\$ 4,658,573</u>	

Investment income, net, for the year ended December 31, 2014 consists of the following:

	2014			
	Unrestricted	Temporarily Restricted	Permanently Restricted	Total
Interest and dividend income	\$ 64,765	\$ 51,517	\$ -0-	\$ 116,282
Net gains (losses) on investments	(33,591)	126,249	-0-	92,658
Investment expenses	(9,116)	(12,728)	-0-	(21,844)
	<u>\$ 22,058</u>	<u>\$ 165,038</u>	<u>\$ -0-</u>	<u>\$ 187,096</u>

Investment income, net, for the year ended December 31, 2013 consists of the following:

	2013			
	Unrestricted	Temporarily Restricted	Permanently Restricted	Total
Interest and dividend income	\$ 122,238	\$ 30,577	\$ -0-	\$ 152,815
Net gains (losses) on investments	(102,120)	278,956	-0-	176,836
Investment expenses	(12,189)	(9,173)	-0-	(21,362)
	<u>\$ 7,929</u>	<u>\$ 300,360</u>	<u>\$ -0-</u>	<u>\$ 308,289</u>

**CURESEARCH FOR CHILDREN'S CANCER**  
**Notes to Financial Statements**  
**December 31, 2014 and 2013**

**Note 3: Fair Value Measurement**

Generally accepted accounting principles establishes a framework for measuring fair value. The framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements).

The three levels of the fair value hierarchy are as follows:

Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets.

Level 2: Inputs to the valuation methodology include:

- Quoted prices for similar assets or liabilities in active markets;
- Quoted prices for identical or similar assets or liabilities in inactive markets;
- Inputs other than quoted prices that are observable for the asset or liability;
- Inputs that are derived principally from or corroborated by observable market data by correlation or other means.

If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability.

Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The asset's or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. The valuation techniques used by CureSearch include the following:

Money Market Funds: Valued at original cost, which equals fair value.

Mutual Funds and Exchange-Traded Funds: Valued at the last sales price reported in the active market in which the individual fund is traded.

Corporate Bonds: Valued using inputs such as benchmark yields, reported trades, broker/dealer quotes and issuer spreads.

In determining the appropriate levels, CureSearch performs a detailed analysis of the assets and liabilities that are subject to fair value measurements.

**CURESEARCH FOR CHILDREN'S CANCER**  
**Notes to Financial Statements**  
**December 31, 2014 and 2013**

**Note 3: Fair Value Measurement (Continued)**

The tables below present the assets measured at fair value on a recurring basis by level within the hierarchy, as of December 31, 2014 and 2013:

	Total	Level 1	Level 2	Level 3
<u>December 31, 2014</u>				
Corporate bonds, fixed income	\$ 3,840,951	\$ -0-	\$ 3,840,951	\$ -0-
Exchange traded funds, equity	1,418,108	1,418,108	-0-	-0-
Money market funds	450,819	450,819	-0-	-0-
Exchange traded funds, fixed income	408,379	408,379	-0-	-0-
Mutual funds, equity	54,403	54,403	-0-	-0-
Mutual funds, international equity	49,551	49,551	-0-	-0-
	<u>\$ 6,222,211</u>	<u>\$ 2,381,260</u>	<u>\$ 3,840,951</u>	<u>\$ -0-</u>
<u>December 31, 2013</u>				
Money market funds	\$ 2,747,630	\$ 2,747,630	\$ -0-	\$ -0-
Corporate bonds, fixed income	2,521,733	-0-	2,521,733	-0-
Exchange traded funds, equity	1,259,191	1,259,191	-0-	-0-
Exchange traded funds, fixed income	372,745	372,745	-0-	-0-
Mutual funds, equity	136,185	136,185	-0-	-0-
Mutual funds, international equity	121,089	121,089	-0-	-0-
	<u>\$ 7,158,573</u>	<u>\$ 4,636,840</u>	<u>\$ 2,521,733</u>	<u>\$ -0-</u>

**Note 4: Property**

Property consisted of the following at December 31, 2014 and 2013:

	2014	2013
Furniture and fixtures	\$ 32,650	\$ 32,650
Leasehold improvements	168,816	30,817
Computer and equipment	311,866	311,866
	<u>513,332</u>	<u>375,333</u>
Less: Accumulated depreciation	<u>370,669</u>	<u>337,202</u>
	<u>\$ 142,663</u>	<u>\$ 38,131</u>

Depreciation expense was \$33,467 and \$65,652 for the years ended December 31, 2014 and December 31, 2013, respectively.

**CURESEARCH FOR CHILDREN'S CANCER**  
**Notes to Financial Statements**  
**December 31, 2014 and 2013**

**Note 5: Temporarily Restricted Net Assets**

CureSearch has several temporarily restricted funds, which may be expended but only for the purpose and subject to restrictions established by the respective donors. Temporarily restricted net assets were available for the following purposes as of December 31, 2014:

	2013		Current Year Activity		2014
		Contributions	Investment	Released from	
			Income	Restrictions	
Acceleration initiative	\$ 10,000	\$ 165,450	\$ -0-	\$ (103,684)	\$ 71,766
Young investigators	505,877	275,200	29,238	(320,368)	489,947
Other research	2,829,793	477,729	135,800	(1,084,769)	2,358,553
Education & resources	140,611	75,150	-0-	(159,352)	56,409
	<u>\$ 3,486,281</u>	<u>\$ 993,529</u>	<u>\$ 165,038</u>	<u>\$ (1,668,173)</u>	<u>\$ 2,976,675</u>

Temporarily restricted net assets were available for the following purposes as of December 31, 2013:

	2012		Prior Year Activity		2013
		Contributions	Investment	Released from	
			Income	Restrictions	
Acceleration initiative	\$ 265,965	\$ 335,000	\$ -0-	\$ (590,965)	\$ 10,000
Young investigators	715,884	100,000	1,428	(311,435)	505,877
Other research	3,954,872	476,212	298,932	(1,900,223)	2,829,793
Education & resources	243,410	90,125	-0-	(192,924)	140,611
	<u>\$ 5,180,131</u>	<u>\$ 1,001,337</u>	<u>\$ 300,360</u>	<u>\$ (2,995,547)</u>	<u>\$ 3,486,281</u>

**Note 6: Permanently Restricted Net Assets**

CureSearch's permanently restricted net assets are composed of two endowment funds, of which the original principal portion of each fund may not be expended.

CureSearch maintains the following endowment funds:

- Corn Fund - This fund was established by The Lovick P. and Elizabeth T. Corn Fund of the Bradley-Turner Foundation and the Beloco Foundation. The principal is permanently restricted. CureSearch can use the investment income, net of expenses, to fund research by physicians/scientists on the faculty of the Section of Pediatric Hematology/Oncology at the Medical College of Georgia. Specific research programs and projects to be funded are to be determined by a Scientific Review Panel, as defined in the agreement, on an annual basis. Based on the occurrence of certain circumstances, as defined in the agreement, the awards can be made to physicians/scientists at other similar tax exempt entities. In addition, expenses incurred by CureSearch to administer this endowment fund may be reimbursed out of the investment income, up to a maximum of 5% of the current year's investment income. The accumulated income and gains (losses) are recorded as temporarily restricted net assets until released.
- Schow Fund - This fund was established by The Schow Foundation. The principal is permanently restricted. CureSearch can use the investment income, net of expenses, to fund research fellowship and young investigator awards. The accumulated income and gains (losses) are recorded as temporarily restricted net assets until released.

**CURESEARCH FOR CHILDREN'S CANCER**  
**Notes to Financial Statements**  
**December 31, 2014 and 2013**

**Note 6: Permanently Restricted Net Assets (Continued)**

The Financial Accounting Standards Board (FASB) issued guidance on the net asset classification of donor-restricted endowment funds for a nonprofit organization that is subject to an enacted version of the Uniform Prudent Management of Institutional Funds Act of 2006 (UPMIFA). This guidance also requires additional disclosures about an organization's endowment funds (both donor-restricted endowment funds and board-designated endowment funds) whether or not the organization is subject to UPMIFA.

The board of directors of CureSearch has interpreted UPMIFA as requiring the preservation of the fair value of the original gift, as of the gift date of the donor-restricted endowment funds, absent explicit donor stipulations to the contrary. As a result of this interpretation, CureSearch classifies as permanently restricted net assets (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund. The remaining portion of the donor-restricted endowment fund that is not classified in permanently restricted net assets is classified as temporarily restricted net assets until those amounts are appropriated for expenditure by CureSearch in a manner consistent with the standard of prudence prescribed by UPMIFA. In accordance with UPMIFA, CureSearch considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds: (1) the duration and preservation of the various funds, (2) the purposes of the donor-restricted endowment funds, (3) general economic conditions, (4) the possible effect of inflation and deflation, (5) the expected total return from income and the appreciation of investments, and (6) other resources of CureSearch.

*Investment Return Objectives, Risk Parameters and Strategies*

CureSearch has adopted investment and spending policies, approved by the board of directors, for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment funds while also maintaining the purchasing power of those endowment assets over the long-term. Accordingly, the investment process seeks to achieve an after-cost total real rate of return, including investment income as well as capital appreciation, which exceeds the annual distribution with acceptable levels of risk. Endowment assets are invested in a well-diversified asset mix that is intended to result in a consistent inflation-protected rate of return that has sufficient liquidity to make an annual distribution of not more than 5%, while growing the funds if possible. Therefore, CureSearch expects its endowment assets, over time, to produce an average annual rate of return that is higher than the inflation rate in order to maintain the purchasing power of the endowment funds. Actual returns in any given year may vary from this amount. Investment risk is measured in terms of the total endowment fund. Investment assets and allocation between asset classes and strategies are managed to not expose the fund to unacceptable levels of risk.

*Spending Policy*

CureSearch has a policy of appropriating for distribution each year not more than 5% of a three-year average of the endowment fund's fair value. In establishing this policy, CureSearch considered the long-term expected return on its investment assets, the nature and duration of the individual endowment funds which must be maintained in perpetuity because of donor-restrictions, and the possible effects of inflation. CureSearch's objective is to maintain the purchasing power of the endowment assets as well as to provide additional real growth through new gifts and investment return.

**CURESEARCH FOR CHILDREN'S CANCER**  
**Notes to Financial Statements**  
**December 31, 2014 and 2013**

**Note 6: Permanently Restricted Net Assets (Continued)**

Endowment net asset composition by type of fund as of December 31, 2014 and 2013 is as follows:

	Unrestricted	Temporarily Restricted	Permanently Restricted	Total Net Endowment Assets
<u>December 31, 2014</u>				
Corn Fund	\$ -0-	\$ 577,132	\$ 1,500,000	\$ 2,077,132
Schow Fund	-0-	18,811	1,000,000	1,018,811
	<u>\$ -0-</u>	<u>\$ 595,943</u>	<u>\$ 2,500,000</u>	<u>\$ 3,095,943</u>
<u>December 31, 2013</u>				
Corn Fund	\$ -0-	\$ 441,531	\$ 1,500,000	\$ 1,941,531
Schow Fund	-0-	41,445	1,000,000	1,041,445
	<u>\$ -0-</u>	<u>\$ 482,976</u>	<u>\$ 2,500,000</u>	<u>\$ 2,982,976</u>

Changes in endowment net assets as of and for the years ended December 31, 2014 and 2013 are as follows:

	Unrestricted	Temporarily Restricted	Permanently Restricted	Endowment Assets
Endowment net assets, December 31, 2012	\$ -0-	\$ 300,368	\$ 2,500,000	\$ 2,800,368
Contributions	-0-	-0-	-0-	-0-
Investment income, net	-0-	105,459	-0-	105,459
Unrealized gains (losses)	-0-	194,901	-0-	194,901
Amounts appropriated for expenditure	-0-	(117,752)	-0-	(117,752)
Endowment net assets, December 31, 2013	-0-	482,976	2,500,000	2,982,976
Contributions	-0-	-0-	-0-	-0-
Investment income, net	-0-	85,841	-0-	85,841
Unrealized gains (losses)	-0-	79,197	-0-	79,197
Amounts appropriated for expenditure	-0-	(52,071)	-0-	(52,071)
Endowment net assets, December 31, 2014	<u>\$ -0-</u>	<u>\$ 595,943</u>	<u>\$ 2,500,000</u>	<u>\$ 3,095,943</u>



**CURESEARCH FOR CHILDREN'S CANCER**  
**Notes to Financial Statements**  
**December 31, 2014 and 2013**

**Note 7: Lease Commitments**

Office Leases: CureSearch leases office space under non-cancellable leases in Bethesda, Maryland; Silver Spring, Maryland; and Charlotte, North Carolina. The Silver Spring lease expired on January 31, 2015 and was not renewed. The Bethesda lease expires in September 2019. The Charlotte lease expires on October 31, 2015. The basic annual rent of all leases is subject to a 3% increase per year. In addition to a base monthly rent payment, the Bethesda and Charlotte leases require that CureSearch pay as additional rent its proportionate share of common area expenses and real estate taxes, as applicable.

Future minimum annual lease payments for each of the years subsequent to December 31, 2014 are as follows:

Year ending December 31:	
2015	\$ 184,100
2016	169,209
2017	174,276
2018	179,514
2019	<u>106,533</u>
	<u>\$ 813,632</u>

CureSearch has entered into separate agreements to sublease portions of its leased premises. One lease, which expired on January 31, 2015 and was not renewed, required monthly rental payments of \$1,300. The second lease expires on October 31, 2015 and the basic annual rent is subject to a 3% increase per year.

Future minimum annual lease payments to be received from these subleases for the year ending December 31, 2015 are \$13,808.

Total rent expense, net of sublease rentals (2014 - \$30,216 and 2013 - \$15,000) for the years ending December 31, 2014 and 2013, including additional rental amounts (2014 - \$4,491 and 2013 - \$8,060) was \$212,480 and \$269,714, respectively.

Equipment Leases: CureSearch leases various office equipment under lease agreements which expire in August 2017. Rent expenses under these leases was \$10,626 and \$8,328 for the years ended December 31, 2014 and 2013, respectively. The minimum annual lease payments for each of the years subsequent to December 31, 2014 are as follows:

Year ending December 31:	
2015	\$ 5,333
2016	5,333
2017	5,333
2018	5,333
2019	<u>3,111</u>
	<u>\$ 24,443</u>

**CURESEARCH FOR CHILDREN'S CANCER**  
**Notes to Financial Statements**  
**December 31, 2014 and 2013**

**Note 8: Pension Plans**

Defined Contribution Benefit Plan: CureSearch sponsors an IRC 403(b) salary deferral retirement plan that generally covers all employees. Under the terms of the plan, participating employees may elect to contribute pre-tax dollars into the plan not to exceed the maximum contribution allowable under applicable provisions of the IRC. Effective January 1, 2013, CureSearch modified the terms of the plan which eliminated all non-elective employer contribution requirements. Effective January 1, 2014, CureSearch modified the terms of the plan to allow for a tiered matching provision which ranges from 0% to 2%. The matching contribution is based on the percentage of the participant's elective deferral to the plan on an annual basis. Participants must have 12 months of service to qualify for an employer match. Contributions made by CureSearch to the plan for the years ended December 31, 2014 and 2013, were \$25,246 and \$-0-, respectively.

Deferred Compensation Plan: During the year ended December 31, 2014, CureSearch adopted a deferred compensation plan under IRC Section 457(b) for the benefit of certain key employees. The Plan became effective December 1, 2014. Under the terms of the plan, participating employees may elect to defer a portion of their compensation on a pre-tax basis into the plan not to exceed the maximum salary deferral amount allowable under the applicable provisions of the IRC. CureSearch may make discretionary contributions to the plan for each participating employee. CureSearch made contributions of \$11,222 to the plan during the year ended December 31, 2014. The deferred compensation amount is held in a separate investment account, referred to as assets held in trust in the statements of financial position.

**Note 9: Grant Commitments**

As of December 31, 2014, CureSearch has outstanding conditional grant commitments to be made totaling \$5,000,223. Grant payments are subject to the fulfillment of certain conditions, as defined in the respective grant agreements. Future expected conditional grant payments for each of the years subsequent to December 31, 2014 are as follows:

Year ending December 31:	
2015	\$ 1,776,084
2016	1,645,485
2017	950,888
2018	627,766
	<u>\$ 5,000,223</u>

**Note 10: Other Matter**

Cash and Cash Equivalents: CureSearch maintains its cash balances in one financial institution. Periodically during the year, CureSearch's cash balances have exceeded federally insured limits. CureSearch has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances.

**CURESEARCH FOR CHILDREN'S CANCER**

**SUPPLEMENTARY INFORMATION**

**DECEMBER 31, 2014 AND 2013**

To the Board of Directors  
CureSearch for Children's Cancer

**Independent Auditor's Report on Supplementary Information**

We have audited the financial statements of CureSearch for Children's Cancer as of and for the years ended December 31, 2014 and 2013, and have issued our report thereon dated July 14, 2015, which contained an unmodified opinion on those financial statements. Our audits were performed for the purpose of forming an opinion on the financial statements as a whole. The supplementary information on the following pages is presented for the purposes of additional analysis and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated in all material respects in relation to the financial statements as a whole.

*Gross, Mendelsohn & Associates, P.A.*

Baltimore, Maryland  
July 14, 2015

**CURESEARCH FOR CHILDREN'S CANCER**  
**Schedules of Functional Expenses**  
**For the Years Ended December 31, 2014 and 2013**

	2014			Total
	Program Services	Fundraising	Management and General	
Personnel expenses	\$ 857,693	\$ 1,515,947	\$ 450,226	\$ 2,823,866
Programmatic initiatives	1,988,211	-0-	-0-	1,988,211
Professional fees	93,395	120,795	334,714	548,904
Facilities expense	93,298	163,960	49,038	306,296
Supplies and services	41,500	134,088	21,813	197,401
Travel expenses	17,318	166,844	9,451	193,613
Public relations	72,093	82,510	33,005	187,608
Bank and merchant fees	-0-	131,219	13,033	144,252
Printing and postage	16,407	11,382	3,404	31,193
Meetings and conferences	23,198	40,735	22,574	86,507
Insurance	24,572	43,631	12,916	81,119
Depreciation	10,194	17,915	5,358	33,467
Registrations, permits and insurance	3,505	6,157	1,841	11,503
Miscellaneous	(30,000)	-0-	-0-	(30,000)
<b>Total Expenses</b>	<b>\$ 3,211,384</b>	<b>\$ 2,435,183</b>	<b>\$ 957,373</b>	<b>\$ 6,603,940</b>

**2013**

<b>Program Services</b>	<b>Fundraising</b>	<b>Management and General</b>	<b>Total</b>
\$ 968,397	\$ 1,279,634	\$ 442,109	\$ 2,690,140
3,911,106	-0-	-0-	3,911,106
124,871	286,880	385,586	797,337
127,877	175,759	60,830	364,466
32,982	71,993	15,569	120,544
11,344	216,228	19,491	247,063
130,987	43,173	12,501	186,661
-0-	167,122	16,092	183,214
19,790	22,331	7,772	49,893
73,696	77,218	16,373	167,287
27,278	37,368	12,976	77,622
23,097	31,569	10,986	65,652
4,204	3,978	1,385	9,567
86,461	3,986	1,388	91,835
<b>\$ 5,542,090</b>	<b>\$ 2,417,239</b>	<b>\$ 1,003,058</b>	<b>\$ 8,962,387</b>

